Abstract:Riyadh S Almalki Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm AL-Qura University, Makkah, Saudi Arabia Correspondence: Riyadh S Almalki, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm AL-Qura University, Makkah, 23335, Saudi Arabia, Email Introduction: Methotrexate (MTX) is one of the most widely used drugs in cancer chemotherapy and treating rheumatoid arthritis. The hepatotoxicity of MTX is one of its major side effects. Roflumilast (ROF) has been recognized to have antioxidant and anti-inflammatory activity in in-vivo and in-vitro models. The present study aimed to explore the potential protective effects of roflumilast against MTX-induced liver toxicity in male Wistar rats. Methods: High dose of 5 mg/kg for 4 consecutive days subcutaneous (S.C) injection of methotrexate for induction of acute liver injury. A total of 24 Wistar rats, rats were used in four different groups. The NS injections were given S.C to the control group once a day for 4 consecutive days. SC injections of MTX (5 mg/kg) were given to the MTX group daily for four days. At 5 mg/kg once daily for four days, the roflumilast group was given daily oral roflumilast. An injection of MTX and oral roflumilast were given to the MTX + roflumilast group once daily for four consecutive days. Results: Administration of high dose MTX (5 mg/kg) today 4 produced a significant decrease in hepatic glutathione (GSH) levels and a significant increase in ALT and AST liver enzymes, hepatic malondialdehyde (MDA), tumor suppressor protein (p53), interleukin 6, interleukin 1 levels compared to the control group. Treatment with roflumilast for 4 days significantly attenuated unfavorable changes in these parameters. According to histopathological findings, Roflumilast significantly reduced MTX-induced inflammation and degeneration in the liver. In conclusion, the findings indicate that roflumilast may have a potential therapeutic benefit in treating rats with MTX-induced liver toxicity by mitigating its effects. Purpose: The aim of this study is to investigate the potential protective effects of roflumilast against MTX-induced liver toxicity in Wistar rats. Keywords: roflumilast, methotrexate, hepatotoxicity, glutathione, malondialdehyde, tumor suppressor protein-53, interleukin 6, interleukin 1 Drug-induced liver toxicity is a major limitation of pharmacotherapy, which can lead to fatal adverse drug reactions and incidence of morbidity and mortality. Anticancer chemotherapeutic agents, when taken for long-term therapy, have been reported to cause many side effects such as cardiotoxicity, lung toxicity, testicular toxicity, and hepatotoxicity. In addition, they cause persistent damage to DNA molecules. 1 Methotrexate (MTX) has anti-proliferative and anti-inflammatory properties and regulatory influence on the immune system. 2 Although known for numerous advantages, MTX use can be detrimental to several viscera, causing serious toxic consequences on respiratory tract, hepatic tissue, and bone marrow. 3 Its side effects have been classified into two groups: those that cause symptoms only, such as nausea, headaches, lethargy, mucositis, and alopecia, and those that could lead to fatal conditions, such as cytopenia, interstitial lung pathology, or MTX-induced pneumonitis, and hepatic conditions, such as fibrosis and cirrhosis. 4 The exact processes or mechanisms responsible for the hepatotoxic effects of MTX are yet to be clearly understood. The effectiveness of MTX as a pharmaceutical agent and its adverse events may be governed by identical or dissimilar metabolic pathways. The pathogenesis of liver toxicity induced by MTX necessitates further investigation. Various processes have been hypothesized to disrupt control mechanisms that safeguard against cellular antioxidants and induce injury to hepatocytes due to oxidative stress. 5 Thus, understanding the mechanisms responsible for both advantageous and detrimental effects of MTX is crucial for identifying new targets for treatment and achieving optimal therapeutic approaches for controlling immune-mediated and inflammatory diseases while reducing detrimental adverse events related to toxicity. This has significant implications for the innovation of new pharmaceutical agents and the development of additional targeted drugs that would improve effectiveness while ameliorating toxic side effects. Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, has been endorsed as a therapeutic agent for inflammatory airway or dermal conditions. A succession of de novo PDE4 inhibiting agents has been designed to moderate inflammation; studies have indicated positive treatment outcomes. 2 Roflumilast has been shown to be an effective anti-in -Abstract Truncated-

Olmesartan Decreased Levels of IL-1β and TNF-α, Down-Regulated MMP-2, MMP-9, COX-2, RANK/RANKL and Up-Regulated SOCs-1 in an Intestinal Mucositis Model

Intestinal Immune Response to Oral Administration Oflactobacillus Reuterir2lc,lactobacillus Plantarumdsm 9843, Pectin and Oatbase on Methotrexateinduced Enterocolitis in Rats

Olmesartan medoxomil self-microemulsifying drug delivery system reverses apoptosis and improves cell adhesion in trinitrobenzene sulfonic acid-induced colitis in rats

Olmesartan niosomes ameliorates the Indomethacin-induced gastric ulcer in rats: Insights on MAPK and Nrf2/HO-1 signaling pathway

The Mechanisms of the Anti-Inflammatory and Anti-Apoptotic Effects of Omega-3 Polyunsaturated Fatty Acids during Methotrexate-Induced Intestinal Damage in Cell Line and in a Rat Model

Novel insights into gut health: Cilostazol strengthens gut integrity by adjusting TLR-2/NF-κB/IL-23 and CD44/AKT/GSK-3β/cyclin-D1 trajectories in methotrexate-induced mucositis model

Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis

Potential Effect of Etoricoxib in Reducing Inflammation in Methotrexate-Induced Pulmonary Injury in Rats: Role of Oxidative Stress and the TLR4/p38-MAPK/NF-κB Signaling Pathway

Oxymatrine alleviates NSAID-associated small bowel mucosal injury by regulating MIP-1/CCR1 signalling and gut microbiota

The Protective Effect of Roflumilast Against Acute Hepatotoxicity Caused by Methotrexate in Wistar Rats: In vivo Evaluation

Molecular mechanisms underlying methotrexate-induced intestinal injury and protective strategies

DOP01 Efficacy and Safety of the IL-6 Trans-Signalling Inhibitor Olamkicept: a Phase 2 Randomized, Placebo-Controlled Trial in Moderately to Severely Active Ulcerative Colitis

AB0100 Mtx combined with ctx inhibited il-6 induced jak2-stat3 activation and the induction of p-gp in peripheral blood lymphocytes of rheumatoid arthritis patients

Albiflorin ameliorates inflammation and oxidative stress by regulating the NF-κB/NLRP3 pathway in Methotrexate-induced enteritis

Methotrexate-induced intestine and nephrotoxicity attenuated by Andrographis paniculata via ameliorating oxidative stress, inflammation and apoptosis

Methotrexate promotes recovery of arthritis-induced alveolar bone loss and modifies the composition of the oral-gut microbiota

p-Cymene and Rosmarinic Acid Ameliorate TNBS-Induced Intestinal Inflammation Upkeeping ZO-1 and MUC-2: Role of Antioxidant System and Immunomodulation

Trans-anethole, the major constituent of the essential oil of anise, improves the antiarthritic effects of methotrexate in rats

Effect of taxifolin on methotrexate-induced oxidative and inflammatory oral mucositis in rats: biochemical and histopathological evaluation

The ınvestigation of the effect of alpha lipoic acid on lung polyphenol oxidase activity in acitretin and methotrexate given rats

The ameliorative impacts of Moringa oleifera leaf extract against oxidative stress and methotrexate-induced hepato-renal dysfunction